Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
WVE
WVE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest WVE ETF News Today | Earnings, Events & Price Alerts
WVE News
Wave Life Sciences Q4 2025 Earnings Call Insights
4d ago
seekingalpha
Wave Life Sciences Reports 2025 Financial Results and Pipeline Progress
4d ago
NASDAQ.COM
Wave Life Sciences Q4 Earnings Report Analysis
4d ago
seekingalpha
Wave Life Sciences Advances Clinical Data Updates and Financial Results
4d ago
Newsfilter
Wave Life Sciences Set to Announce Q4 Earnings Results
5d ago
seekingalpha
Shifting Trends in Biotechnology Mergers and Acquisitions
Feb 19 2026
Globenewswire
Latest Wall Street Rating Updates
Feb 05 2026
CNBC
Wave Life Sciences Regains Full Rights to WVE-006 from GSK
Feb 02 2026
Benzinga
Wave Life Sciences Regains AATD Asset WVE-006 from GSK
Feb 02 2026
seekingalpha
Wave Life Sciences Advances WVE-006 Therapeutic Program
Feb 02 2026
Newsfilter
Eli Lilly and Novo Nordisk Drive Diversification in Obesity Drug Market
Jan 23 2026
CNBC
Wave Life Sciences (WVE) Director Exercises 42,000 Options, Sells for $630,000
Jan 14 2026
Fool
Wave Life Sciences Director Adrian Rawcliffe Sells 42,000 Shares for ~$630,000
Jan 14 2026
NASDAQ.COM
Anticipate a Hectic Year for Obesity Medications with New Pills Launching
Jan 12 2026
Barron's
Wave Life Sciences to Initiate WVE-007 Trials in 2026 with $602 Million Cash Reserves
Jan 12 2026
Globenewswire
Arrowhead Drug Enhances Eli Lilly's Zepbound Weight Loss Results in Initial Trial
Jan 06 2026
Barron's
Show More News
